Cardiovascular Diagnostic Testing Market Current Trends and Restraints Forecast To 2031

The global cardiovascular diagnostic testing market revenue was US$ 6,876.27 million in 2020. The global cardiovascular diagnostic testing market revenue is forecast to reach US$ 15,430.44 million by 2030, growing at a compound annual growth rate (CAGR) of 8.1% during the forecast period from 2021-2030.

The term cardiovascular diseases (CVDs) refers to a group of conditions related to the heart and blood vessels, including coronary heart disease, cerebrovascular disease, and rheumatic heart disease.

Approximately four out of five CVD deaths occur from heart attacks and strokes, and one-third of these deaths happen prematurely in people under age 70. Millions of people worldwide die every year from acute cardiovascular events, making it one of the leading causes of morbidity and mortality in humans.

Factors Influencing Market Growth

An increase in geriatrics population, an increase in cardiovascular disease prevalence, and an increase in unhealthy diets and a sedentary lifestyle contribute to the growth of the cardiovascular diagnostic testing market.The development of treatment procedures and technological advancements in the cardiovascular diagnostic testing market support its growth.

Download free sample of this report :-https://www.quadintel.com/request-sample/cardiovascular-diagnostic-testing-market/QI040

Due to federal regulations and guidance for laboratory-developed tests (LDTs), limited insurance coverage, and high costs of devices used in diagnostic testing for cardiovascular diseases, the market for cardiovascular diagnostic testing may have slow growth.

The developing economies of Asia-Pacific and LAMEA present lucrative opportunities for cardiovascular diagnostic testing due to improvements in healthcare infrastructure and a rise in patient demand for better healthcare services.

Impact Analysis of COVID-19

COVID-19 pandemic had positively impacted the global cardiovascular diagnostic testing market. A rising prevalence of conditions like diabetes, heart disease, and others makes patients more vulnerable to COVID-19. Moreover, patients with pre-existing heart disease who suffer from COVID-19 are more likely to suffer a heart attack or develop congestive heart failure.

The National Health Commission reports that 35% of COVID-19 patients suffer from hypertension and 17% from heart disease. A reliable diagnostic test and the swift development of innovative assays have become more important in the wake of the COVID-19 outbreak. Furthermore, Coronavirus infection damages the inner walls of veins and arteries, which can cause inflammation, leakage, and blood clots, which can compromise blood flow to the heart or other parts of the body. Due to this, timely diagnosis becomes vital if one has a pre-existing heart condition.

Regional Insights

Region-wise, North America held dominance in the global market and is forecast to maintain its position during the forecast period. This is primarily due to a rise in coronary disease incidences. This region is commonly associated with high blood pressure, high- and low-density lipoprotein cholesterol, and smoking, which can all contribute to a rise in heart diseases.

Request full Report Description, TOC, Table of Figure, Chart, etc : -https://www.quadintel.com/request-sample/cardiovascular-diagnostic-testing-market/QI040

Leading Competitors

The leading prominent companies profiled in the global cardiovascular diagnostic testing market are:

Abbott Laboratories
Becton, Dickinson, and Company
bioMrieux, Inc.
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd
PerkinElmer, Inc.
Siemens AG
Thermo Fisher Scientific, Inc.
Tosoh Corporation
Other Prominent Players

Scope of the Report

The global cardiovascular diagnostic testing market segmentation focuses on Type, End-User, and Region.

Segmentation based on Type

Laboratory Developed Test
Lipoprotein Test
Angiotensin Test
Fibrinogen Test
Serum Uric Acid Test
High-sensitivity C-reactive protein (hs-CRP)
In-Vitro Diagnostic Test
Electrocardiogram Test
Echocardiography Test
Transesophageal Echocardiogram Test
Others

Download Free Sample Report -https://www.quadintel.com/request-sample/cardiovascular-diagnostic-testing-market/QI040

Segmentation based on End-User

Laboratory Testing Facilities
Academic Institutes
Point-of-care Testing Facilities

Segmentation based on Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America

Request full Report :-https://www.quadintel.com/request-sample/cardiovascular-diagnostic-testing-market/QI040

About Quadintel:

We are the best market research reports provider in the industry. Quadintel believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in today's competitive environment. Quadintel is a 'one-stop solution' for individuals, organizations, and industries that are looking for innovative market research reports.

We will help you in finding the upcoming trends that will entitle you as a leader in the industry. We are here to work with you on your objective which will create an immense opportunity for your organization. Our priority is to provide high-level customer satisfaction by providing innovative reports that enable them to take a strategic decision and generate revenue. We update our database on a day-to-day basis to provide the latest reports. We assist our clients in understanding the emerging trends so that they can invest smartly and can make optimum utilization of resources available.

Get in Touch with Us:

Quadintel:
Email:sales@quadintel.com
Address: Office - 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
Tel: +1 888 212 3539 (US - TOLL FREE)
Website : https://www.quadintel.com/

This release was published on openPR.